HomeNewsBusinessEarningsRanbaxy Q3 net may rise 83.5% at Rs 112cr: Motilal Oswal

Ranbaxy Q3 net may rise 83.5% at Rs 112cr: Motilal Oswal

Sales of Ranbaxy Laboratories are expected to increase by 2.8 percent Q-o-Q (up 15.7 percent Y-o-Y) to Rs 2879.1 crore, according to Motilal Oswal.

February 05, 2014 / 10:09 IST
Story continues below Advertisement

Motilal Oswal has come out with its third quarter (October-December) earnings estimates for the healthcare sector. The brokerage house expects Ranbaxy Laboratories to report a 83.5 percent growth quarter-on-quarter in net profit at Rs 112.1 crore.

Sales of Ranbaxy Laboratories are expected to increase by 2.8 percent Q-o-Q (up 15.7 percent Y-o-Y) to Rs 2879.1 crore, according to Motilal Oswal.

Story continues below Advertisement

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 20.5 percent Q-o-Q (up 467.1 percent Y-o-Y) to Rs 233.5 crore.

Motilal Oswal on Ranbaxy Laboratories: